M Merck
| Market Cap | $298.84B |
| P/E Ratio | 16.60 |
| Forward P/E | 12.41 |
| Dividend Yield | 2.81% |
| Beta | 0.28 |
| 52W Range | $70.89 - $123.02 |
| # Hedge Funds | 10 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Hedge Fund Ownership
| Investor 10 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Kahn Brothers Group Kahn Brothers Group | 8.02% | $45.27M | 430,103 | Reduce 0.84% |
| Bill Nygren Harris Associates LP | 1.87% | $1.48B | 14,088,705 | Add 43.42% |
| Sarah Ketterer Causeway Capital Management | 1.51% | $109.96M | 1,044,617 | Reduce 7.89% |
| Prem Watsa Fairfax Financial Holdings | 0.87% | $18.20M | 172,900 | — |
| Christopher Bloomstran Semper Augustus Investments | 0.54% | $4.68M | 44,443 | — |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.50% | $15.41M | 146,456 | Reduce 0.83% |
| Mairs & Power Growth Fund Mairs & Power Inc | 0.05% | $5.47M | 51,999 | Reduce 0.36% |
| David Katz Matrix Asset Advisors | 0.03% | $301.00K | 2,862 | Reduce 0.28% |
| Dodge & Cox Dodge & Cox | 0.01% | $14.55M | 138,205 | Reduce 10.42% |
| Richard Pzena Pzena Investment Management | 0.00% | $349.00K | 3,324 | — |
Insider Trading
| Insider Name of the company insider who made the trade 34 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Guindo ChirfiChief Marketing Officer | Sale | 10,000 | $121.46 | $1.21M | 12 Feb 2026 | 12 Feb 2026 |
| Li Dean YExecutive VP & President, MRL | Sale | 10,235 | $117.52 | $1.20M | 10 Feb 2026 | 10 Feb 2026 |
| Dean Y LiExecutive VP & President, MRL | Sale | 10,235 | $117.52 | $1.20M | 10 Feb 2026 | 10 Feb 2026 |
| Zachary JenniferEVP, General Counsel | Sale | 56,792 | $119.15 | $6.77M | 09 Feb 2026 | 09 Feb 2026 |
| Zachary JenniferEVP, General Counsel | Sale | 38,835 | $119.15 | $4.63M | 09 Feb 2026 | 09 Feb 2026 |
| Zachary JenniferEVP, General Counsel | Sale | 25,946 | $119.15 | $3.09M | 09 Feb 2026 | 09 Feb 2026 |
| Guindo ChirfiChief Marketing Officer | Sale | 10,000 | $118.41 | $1.18M | 09 Feb 2026 | 09 Feb 2026 |
| Jennifer ZacharyEVP, General Counsel | Sale | 25,946 | $119.15 | $3.09M | 09 Feb 2026 | 09 Feb 2026 |
| Chirfi GuindoChief Marketing Officer | Sale | 10,000 | $118.41 | $1.18M | 09 Feb 2026 | 09 Feb 2026 |
| Jennifer ZacharyEVP, General Counsel | Sale | 38,835 | $119.15 | $4.63M | 09 Feb 2026 | 09 Feb 2026 |
| Jennifer ZacharyEVP, General Counsel | Sale | 56,792 | $119.15 | $6.77M | 09 Feb 2026 | 09 Feb 2026 |
| Williams David MichaelEVP,Chief Info&Digital Officer | Sale | 5,000 | $121.91 | $609.52K | 06 Feb 2026 | 06 Feb 2026 |
| Oosthuizen Johannes JacobusPresident, U.S. Market | Sale | 15,000 | $121.87 | $1.83M | 06 Feb 2026 | 06 Feb 2026 |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | 37,685 | $120.92 | $4.56M | 06 Feb 2026 | 06 Feb 2026 |
| David Michael WilliamsEVP,Chief Info&Digital Officer | Sale | 5,000 | $121.91 | $609.52K | 06 Feb 2026 | 06 Feb 2026 |
| Johannes Jacobus OosthuizenPresident, U.S. Market | Sale | 15,000 | $121.87 | $1.83M | 06 Feb 2026 | 06 Feb 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | Sale | 37,685 | $120.92 | $4.56M | 06 Feb 2026 | 06 Feb 2026 |
| Guindo ChirfiChief Marketing Officer | Sale | 20,000 | $121.88 | $2.44M | 05 Feb 2026 | 06 Feb 2026 |
| Chirfi GuindoChief Marketing Officer | Sale | 20,000 | $121.88 | $2.44M | 05 Feb 2026 | 06 Feb 2026 |
| Smart Dalton E. IIISVP Fin. - Global Controller | Sale | 2,400 | $119.68 | $287.22K | 04 Feb 2026 | 06 Feb 2026 |
| Smart Dalton E. IIISVP Fin. - Global Controller | Sale | 4,000 | $119.68 | $478.70K | 04 Feb 2026 | 06 Feb 2026 |
| Litchfield CarolineEVP & CFO | Sale | 41,997 | $119.61 | $5.02M | 04 Feb 2026 | 06 Feb 2026 |
| Li Dean YExecutive VP & President, MRL | Sale | 15,087 | $118.77 | $1.79M | 04 Feb 2026 | 06 Feb 2026 |
| Davis Robert MChairman, CEO & President | Sale | 32,462 | $118.35 | $3.84M | 04 Feb 2026 | 06 Feb 2026 |
| Davis Robert MChairman, CEO & President | Sale | 14,972 | $117.38 | $1.76M | 04 Feb 2026 | 06 Feb 2026 |
| Dalton E. Smart IIISVP Fin. - Global Controller | Sale | 2,400 | $119.68 | $287.22K | 04 Feb 2026 | 06 Feb 2026 |
| Dalton E. Smart IIISVP Fin. - Global Controller | Sale | 4,000 | $119.68 | $478.70K | 04 Feb 2026 | 06 Feb 2026 |
| Robert M DavisChairman, CEO & President | Sale | 32,462 | $118.35 | $3.84M | 04 Feb 2026 | 06 Feb 2026 |
| Caroline LitchfieldEVP & CFO | Sale | 41,997 | $119.61 | $5.02M | 04 Feb 2026 | 06 Feb 2026 |
| Dean Y LiExecutive VP & President, MRL | Sale | 15,087 | $118.77 | $1.79M | 04 Feb 2026 | 06 Feb 2026 |
| Robert M DavisChairman, CEO & President | Sale | 14,972 | $117.38 | $1.76M | 04 Feb 2026 | 06 Feb 2026 |
| Downing Cristal NChief Comm. & Public Afrs Ofcr | Sale | 7,085 | $87.00 | $616.39K | 10 Nov 2025 | 12 Nov 2025 |
| Williams David MichaelEVP,Chief Info&Digital Officer | Sale | 8,614 | $83.59 | $720.04K | 03 Nov 2025 | 04 Nov 2025 |
| David Michael WilliamsEVP,Chief Info&Digital Officer | Sale | 8,614 | $83.59 | $720.04K | 03 Nov 2025 | 04 Nov 2025 |
Frequently Asked Questions
What is MRK stock price today?
Merck (MRK) is currently trading at $120.87. The stock has a 52-week range of $70.89 to $123.02 and a market capitalization of $298.84B.
Is MRK a good stock to buy in 2026?
Merck has a P/E ratio of 16.6 (forward P/E: 12.4), a dividend yield of 2.81%, and 1-year performance of +45.0%. 10 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling MRK stock?
There have been 34 insider transactions for MRK in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has MRK stock performed over the past year?
Merck (MRK) has returned +45.0% over the past 12 months. The stock traded between $70.89 and $123.02 during this period, and is currently at $120.87.
Which hedge funds own MRK (Merck)?
10 tracked hedge funds currently hold MRK in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is MRK's market cap and valuation?
Merck (MRK) has a market capitalization of $298.84B. The trailing P/E ratio is 16.6 and forward P/E is 12.4. The stock is classified in the Healthcare sector.
What is MRK's revenue and profitability?
Merck reported revenue of $65.01B with net income of $18.25B and a profit margin of 0.28%. The stock has a beta of 0.28.
What sector is MRK in and who are its biggest institutional holders?
Merck (MRK) operates in the Healthcare sector. It is held by 10 tracked hedge funds. See the ownership table above for the complete list.